PhorMed
Utilizing gene therapy to target cancer and mutated cells
Analytics
Raised: $196,051
Aggregate Commitments $
Platform
StartEngine
Start Date
05/24/2022
Close Date
08/17/2022
Min. Goal
$10,000
Max. Goal
$2,150,494
Min. Investment
$500
Security Type
Equity - Common
Funding Type
RegCF
Series
Seed
Price Per Share
$1.00
Pre-Money Valuation
$51,647,023
Rolling Commitments $
Status
Active
Reporting Date
06/25/2022
Days Remaining
53
% of Min. Goal
1,961%
% of Max. Goal
9%
Likelihood of Max
Avg. Daily Raise
$6,127
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Location
Beverly Hills, California
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
PhorMed, with a valuation of $51.6 million, is raising funds on StartEngine. It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and is developing a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes. Ben Chang founded PhorMed in May 2019. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $2,150,494. The campaign proceeds will be used for growth and expansion.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-573,854 |
$-948,160 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$105,694 |
$109,844 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$183,724 |
$340,922 |
|
Short-Term Debt |
$227,264 |
$363,294 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$227,264 |
$363,294 |
Financials as of: 05/24/2022
Create a free account today to gain access to KingsCrowd analytics.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
